{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-029142","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.769149+00:00","generated_at":"2026-06-27T10:38:00.114733+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CytomX promotes Amy Peterson to President and COO; salary, equity grants disclosed","bullets":["Dr. Peterson promoted to President and COO effective Feb 2, 2022; previously EVP & Chief Dev. Officer.","Annual base salary increased to $550,000; discretionary annual bonus target set at 50% of salary.","Received option for 200,000 shares at $4.13 strike price and 40,000 restricted stock units.","Dr. Sean McCarthy continues as Chairman and CEO; Peterson assumes President role formerly held by McCarthy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-029142","json":"https://secwatch.observer/filing/0001193125-22-029142.json","markdown":"https://secwatch.observer/filing/0001193125-22-029142.md","text":"https://secwatch.observer/filing/0001193125-22-029142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/d198997d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:38:00.114733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"076a06ebe0","claim":"Sean McCarthy changed role as Chairman and Chief Executive Officer at CytomX Therapeutics, Inc..","evidence_excerpt":"Dr. Sean McCarthy will continue in his positions as Chairman and Chief Executive Officer of the Company, while Dr. Peterson assumes the title of President previously held by Dr. McCarthy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Role","value":"Chairman and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b404fdb1a5","claim":"Amy Peterson changed role as President and Chief Operating Officer at CytomX Therapeutics, Inc..","evidence_excerpt":"On February 2, 2022, the Board of Directors of CytomX Therapeutics, Inc. (the “Company”) promoted Dr. Amy Peterson to serve as President and Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522029142/0001193125-22-029142-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}